Skip to main content
. 2005 Jan 14;23(17):2273–2279. doi: 10.1016/j.vaccine.2005.01.033

Fig. 2.

Fig. 2

ALT level following rMVA immunization and SARS-CoV challenge. Panel A: pre-challenge (ferret #8 sample not available); panel B: 3–5 days post infection (dpi) with SARS-CoV (ferret #3 sample not available); panel C: 12–14 dpi (ferret #8 sample not available); panel D: 19–21 dpi; panel E: 27–29 dpi; the ALT value between the dotted scale line is considered as normal reference value.